<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508869</url>
  </required_header>
  <id_info>
    <org_study_id>MG-DYS-ROS</org_study_id>
    <nct_id>NCT03508869</nct_id>
  </id_info>
  <brief_title>Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skin Laser &amp; Surgery Specialists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Skin Laser &amp; Surgery Specialists</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Mirvaso® Gel and Dysport® for erythema and flushing of&#xD;
      Rosacea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the improvement of facial erythema and flushing while using Mirvaso® and Dysport®&#xD;
      treatments based on the clinician's and patient's assessments using a verified 5-point&#xD;
      grading scale&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sponsor asked site to suspend study.&#xD;
  </why_stopped>
  <start_date type="Actual">September 27, 2016</start_date>
  <completion_date type="Actual">September 20, 2017</completion_date>
  <primary_completion_date type="Actual">September 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Assessments for Erythema</measure>
    <time_frame>6 months</time_frame>
    <description>% of subjects who achieve a grade of 0 or 1 on the 5-point grading scale for Erythema 6 months post Dysport treatment Subject achieving a grade of 0 or 1 or ≥ 2 grade of improvement from baseline at 6 months for Erythema on the 5-point grading scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Assessments for Flushing</measure>
    <time_frame>6 months</time_frame>
    <description>% of subjects who achieve a grade of 0 or 1 on the 5-point grading scale for Flushing 6 months post Dysport treatment Subject achieving a grade of 0 or 1 or ≥ 2 grade of improvement from baseline at 6 months for Flushing on the 5-point grading scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>6 months</time_frame>
    <description>Safety evaluations will be performed at all visits. Adverse events, local tolerability (dryness, pruritus burning/stinging) and a facial exam will be performed for all visits.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Erythema and Flushing Associated With Rosacea</condition>
  <arm_group>
    <arm_group_label>Mirvaso® (brimonidine) topical gel, 0.33%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dysport®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dysport® in conjunction with Mirvaso</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dysport® in conjunction with Mirvaso</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirvaso® (brimonidine) topical gel, 0.33%</intervention_name>
    <description>Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.</description>
    <arm_group_label>Mirvaso® (brimonidine) topical gel, 0.33%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport®</intervention_name>
    <description>Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.</description>
    <arm_group_label>Dysport®</arm_group_label>
    <other_name>Dysport® (abobotulinumtoxinA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%</intervention_name>
    <description>Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%</description>
    <arm_group_label>Dysport® in conjunction with Mirvaso</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female&#xD;
&#xD;
          2. 18 years of age or older&#xD;
&#xD;
          3. Clinical diagnosis of rosacea&#xD;
&#xD;
          4. Moderate to severe persistent facial erythema associated with rosacea at baseline, as&#xD;
             determined by: a grade of greater than or equal to 3 on the 5 point grading scale1&#xD;
             (Figure 1)&#xD;
&#xD;
          5. No known medical conditions that may interfere with study participation&#xD;
&#xD;
          6. Willingness to not use any products on their face for the duration of the study&#xD;
&#xD;
          7. Read, understand, and sign informed consent forms&#xD;
&#xD;
          8. Willingness to sign photography release form&#xD;
&#xD;
          9. Willing and able to comply with all follow-up requirements&#xD;
&#xD;
         10. Willingness to undergo treatment using Mirvaso® Gel and Dysport®&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any significant skin disease at treatment area&#xD;
&#xD;
          2. Any medical condition which could interfere with the treatment&#xD;
&#xD;
          3. Inability or unwillingness to follow the treatment schedule&#xD;
&#xD;
          4. Inability or unwillingness to sign the informed consent&#xD;
&#xD;
          5. Pregnant or lactating&#xD;
&#xD;
          6. Allergy to cow's milk protein&#xD;
&#xD;
          7. Previous or current use of Mirvaso® Gel&#xD;
&#xD;
          8. Known hypersensitivity to Dysport® , Mirvaso® Gel or any of their ingredients&#xD;
&#xD;
          9. Previous Dysport® treatment 6 months prior to the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skin Laser &amp; Surgery Specialists</investigator_affiliation>
    <investigator_full_name>David J. Goldberg, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Erythema</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

